12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GLPG0634: Phase IIb start

Galapagos said partner AbbVie will provide an additional $20 million to expand the number of patients to 875 in a planned international Phase IIb trial to evaluate GLPG0634. Galapagos, which declined to disclose the original number of patients, said the payment is in addition to the $150 million upfront under the partners' February 2012 deal to develop GLPG0634. The trial,...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >